Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD—disease outcome and response to therapy

B Verstockt, NM Noor, UM Marigorta… - Journal of Crohn's …, 2021 - academic.oup.com
Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme
phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent …

Challenges in IBD research: precision medicine

LA Denson, M Curran, DPB McGovern… - Inflammatory bowel …, 2019 - academic.oup.com
Precision medicine is part of five focus areas of the Challenges in IBD research document,
which also includes preclinical human IBD mechanisms, environmental triggers, novel …

New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes

EL Barnes, R Burakoff - Inflammatory bowel diseases, 2016 - academic.oup.com
Despite advances in our understanding of the pathophysiology underlying inflammatory
bowel disease, there remains a significant need for biomarkers that can differentiate …

[HTML][HTML] Precision medicine in inflammatory bowel disease: concept, progress and challenges

SP Borg-Bartolo, RK Boyapati, J Satsangi… - F1000Research, 2020 - ncbi.nlm.nih.gov
Crohn's disease and ulcerative colitis are increasingly prevalent, relapsing and remitting
inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their …

The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1

F Imhann, KJ Van der Velde, R Barbieri, R Alberts… - BMC …, 2019 - Springer
Background Inflammatory bowel disease (IBD) is a chronic complex disease of the
gastrointestinal tract. Patients with IBD can experience a wide range of symptoms, but the …

Precision medicine in IBD: genes, drugs, bugs and omics

R Mao, M Chen - Nature Reviews Gastroenterology & Hepatology, 2022 - nature.com
Key studies published in 2021 demonstrated mechanisms that drive macrophage–fibroblast
pathogenicity in Crohn's disease, developed multi-omics profiles to predict response to …

Time to revisit disease classification in inflammatory bowel disease: is the current classification of inflammatory bowel disease good enough for optimal clinical …

B Verstockt, B Bressler, H Martinez-Lozano… - Gastroenterology, 2022 - Elsevier
Inflammatory bowel disease (IBD), historically subdivided into Crohn's disease and
ulcerative colitis, is a very heterogeneous condition. While the tendency in medicine is to try …

PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial

M Parkes, NM Noor, F Dowling, H Leung, S Bond… - BMJ open, 2018 - bmjopen.bmj.com
Background The course of Crohn's disease (CD) varies substantially between individuals,
but reliable prognostic markers do not exist. This hinders disease management because …

Biomarkers in search of precision medicine in IBD

RK Boyapati, R Kalla, J Satsangi… - Official journal of the …, 2016 - journals.lww.com
The completion of the human genome project in 2003 represented a major scientific
landmark, ushering in a new era with hopes and expectations of fresh insights into disease …

Inflammatory bowel disease: complexity and variability need integration

C Fiocchi - Frontiers in Medicine, 2018 - frontiersin.org
In the last century, humanity has being increasingly affected by a large number of chronic
conditions that fall into two major categories: neoplastic and inflammatory diseases. Unlike …